IN2013MU02911A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02911A
IN2013MU02911A IN2911MU2013A IN2013MU02911A IN 2013MU02911 A IN2013MU02911 A IN 2013MU02911A IN 2911MU2013 A IN2911MU2013 A IN 2911MU2013A IN 2013MU02911 A IN2013MU02911 A IN 2013MU02911A
Authority
IN
India
Prior art keywords
relates
pharmaceutical compositions
sodium picosulfate
citric acid
magnesium oxide
Prior art date
Application number
Inventor
Muthaiyyan Essakimuthu Kannan
Jitendra Rameshchandra Patel
Paritosh Kunwar Singh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN2911MU2013 priority Critical patent/IN2013MU02911A/en
Priority to US14/482,678 priority patent/US20150072014A1/en
Publication of IN2013MU02911A publication Critical patent/IN2013MU02911A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)

Abstract

PHARMACEUTICAL COMPOSITIONS OF SODIUM PICOSULFATE, MAGNESIUM OXIDE AND CITRIC ACID ABSTRACT The present invention relates to pharmaceutical compositions of sodium picosulfate, magnesium oxide and citric acid, in particular, the invention relates to pharmaceutical compositions comprise granules having a layer of sodium picosulfate on neutral carrier/s and also relates to processes for the preparation of such compositions and use thereof for bowel cleansing.
IN2911MU2013 2013-09-10 2013-09-10 IN2013MU02911A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN2911MU2013 IN2013MU02911A (en) 2013-09-10 2013-09-10
US14/482,678 US20150072014A1 (en) 2013-09-10 2014-09-10 Pharmaceutical Compositions of Sodium Picosulfate, Magnesium Oxide and Citric Acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2911MU2013 IN2013MU02911A (en) 2013-09-10 2013-09-10

Publications (1)

Publication Number Publication Date
IN2013MU02911A true IN2013MU02911A (en) 2015-07-03

Family

ID=52625867

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2911MU2013 IN2013MU02911A (en) 2013-09-10 2013-09-10

Country Status (2)

Country Link
US (1) US20150072014A1 (en)
IN (1) IN2013MU02911A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101420315B1 (en) 2014-03-19 2014-07-17 남봉길 Pharmaceutical liquid composition
US20160220492A1 (en) * 2015-01-31 2016-08-04 Gavis Pharmaceuticals Pharmaceutical composition of sodium picosulfate
RU2018105869A (en) * 2015-08-17 2019-09-19 Ферринг Б.В. LIQUID COMPOSITIONS CONTAINING PICOSULFATE AND MAGNESIUM CITRATE
CN105456264B (en) * 2015-12-03 2018-07-10 广州瑞尔医药科技有限公司 Pharmaceutical composition of economic benefits and social benefits laxative and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0724441A1 (en) * 1993-10-19 1996-08-07 The Procter & Gamble Company Picosulphate dosage form
CN101820859B (en) * 2007-10-12 2013-05-01 辉凌国际制药（瑞士）有限公司 Process for the manufacure of pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate
NZ704014A (en) * 2012-07-27 2017-10-27 Redhill Biopharma Ltd Formulations and methods of manufacturing formulations for use in colonic evacuation

Also Published As

Publication number Publication date
US20150072014A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
PH12016501122A1 (en) Delayed release compositions of linaclotide
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX366899B (en) New compounds.
MA39710A (en) Topical composition for use in the treatment of inflammatory bowel disease
PH12014501991B1 (en) Phenicol antibacterials
IN2015DN03327A (en)
TN2012000457A1 (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
IN2013MU03583A (en)
TR201910866T4 (en) Combined preparations for cancer treatment.
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PL2841548T3 (en) Formulations, use of same as or for manufacture of dish-washing agents and their manufacture
PL2961822T3 (en) Formulations, use of same as or for manufacture of dishwashing agents and their manufacture
IN2013MU03373A (en)
IN2013MU02911A (en)
PL2989192T3 (en) Formulations, use of same as or for manufacture of dish-washing agents and their manufacture
EP2983684B8 (en) Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations
MX370990B (en) Esters of oligo-hydroxycarboxylic acids and use thereof.
NZ715615A (en) Pharmaceutical compositions of ranolazine and dronedarone
WO2015044434A3 (en) Fluor-9-methyl-β-carbolines
GB2527233A (en) Composition comprising hydrocortisone
MY168952A (en) Fe (iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
WO2014122671A3 (en) Solid oral compositions of saxagliptin